Overview of Glicerin-Teva

Quick Facts

Property	Description
Active ingredient	Glycerol (INN)
Form	Suppository or Rectal Solution
Pharmacological class	Osmotic Laxative / Hyperosmotic Agent
Common purpose	Relief of occasional constipation and hardened stool
Origin	Highly purified, derived polyol compound

Defining Glicerin-Teva: Classification and Purpose

Glicerin-Teva is a pharmaceutical preparation marketed by Teva Pharmaceutical Industries Ltd. and classified as an osmotic laxative, primarily used to provide relief from occasional constipation and the discomfort associated with dry or hardened stool conditions. The preparation relies on the active substance Glycerol to fulfill this therapeutic purpose. This mechanism facilitates the correction of functional constipation by drawing water into the colon.

As an osmotic laxative, Glicerin-Teva's action is fundamentally distinct from that of stimulant or contact-based alternatives. The core function of Glycerol as a hygroscopic agent is to increase the fluid content of the feces by drawing water from the surrounding tissues. This process, combined with a gentle lubricating effect, ensures that the stool mass is softened and easier to pass, which is particularly useful for patient groups where straining must be minimized.

Composition and Localized Form

The sole active ingredient in this preparation is Glycerol (INN), which is chemically identified as Propane-1,2,3-triol. The product is defined as a single active ingredient formulation. To maximize its local, non-systemic effect, Glicerin-Teva is typically presented in dosage forms suitable for the rectal route of administration, most commonly as a suppository or, in some variations, an aqueous rectal solution. This focus on local delivery contrasts with oral osmotic agents like polyethylene glycol.

In the suppository form, the Glycerol is integrated into an inert base, such as solidified fatty acids or gelatin. This base dissolves or melts rapidly upon insertion, immediately releasing the active agent. This formulation ensures the preparation's effectiveness relies on direct physical properties at the site of action, confirming its classification as a local hyperosmotic agent suitable for both adult and pediatric patient groups, depending on the specific dosage strength.

What side effects are possible with Glicerin-Teva?

Possible side effects and safety information

Official regulatory documents classify the safety profile of Glicerin-Teva (Glycerol suppositories) primarily around localized effects, consistent with its non-systemic, rectal route of administration. The most commonly documented adverse reactions, which fall under Gastrointestinal Disorders, include localized reactions such as rectal irritation, rectal discomfort, a burning sensation, and abdominal cramps.

Specific frequency categories (such as Very Common, Common, or Rare) are often Not Defined for these localized events in official labeling, though they are acknowledged as possible occurrences during use.

Serious Adverse Reactions and Safety Constraints

The label identifies certain reactions that warrant attention. These serious adverse reactions include signs of hypersensitivity (allergic reaction), such as rash or swelling, as well as clinically significant outcomes like rectal bleeding or severe abdominal pain. Failure to have a bowel movement after use is also noted as a safety concern, potentially indicating an underlying issue.

Safety documents also specify constraints for use. The risk of laxative dependence and diarrhea is explicitly noted in association with prolonged or excessive daily use. Regulatory information also addresses specific populations, advising avoidance during the first trimester of pregnancy and including a note that the product may interfere with glucose control in patients with diabetes. Contraindications to use include known hypersensitivity to Glycerol or the presence of pre-existing conditions such as intestinal obstruction.

Overdose and Emergency Response

Overdose and when to seek help

Overdose or excessive use of Glicerin-Teva is officially documented to result primarily from the hyperosmotic activity of Glycerol, leading to both local and potential systemic effects.

Documented Manifestations and Consequences: Excessive use is documented to cause severe diarrhea, abdominal cramping, and rectal irritation. The most serious consequence described in regulatory labeling is the potential for significant fluid loss, which can progress to severe dehydration and critical electrolyte imbalances, such as hypokalemia. This risk is specifically noted for vulnerable populations, including elderly and pediatric patients.

When to Seek Immediate Medical Help: Regulatory authorities explicitly mandate that immediate medical attention is required if accidental oral ingestion occurs, or if serious signs of overdose develop. These serious signs include passing out, trouble breathing, or clinical manifestations of severe dehydration such as unusual thirst or decreased urination. The official management of an overdose is defined as entirely symptomatic and supportive, focusing on the correction of fluid and electrolyte status. No specific antidote is known for this preparation.

The regulatory profile explicitly directs users to seek urgent medical assistance when symptoms of severe fluid loss or collapse are observed.

Therapeutic Uses of Glicerin-Teva

What Glicerin-Teva Treats: Main Uses and Benefits

The preparation is commonly used for the symptomatic relief of occasional constipation, addressing acute and short-term episodes when bowel movements become difficult or infrequent. The product is indicated for symptoms associated with the lower bowel. The therapeutic benefit is applied across domains where additional symptomatic support is needed and contributes to support for relief during acute episodes associated with a delay in evacuation.

The preparation is relevant for easing symptoms that may become disruptive, including hard, dry stool, defecatory straining, and infrequent bowel movements. Glicerin-Teva supports general well-being during symptomatic phases, and is commonly used when short-term symptomatic assistance is needed, such as in post-operative recovery or managing rectally localized fecal impaction. It is commonly used to help with supportive relief and contributes to easing the physical effort during defecation.

Quick Fact: Symptomatic Support for Hard Stool
Symptom Domain: Difficulty passing hard, dry stool
Key Benefit: Helps with supportive relief during acute episodes
Relevant Context: Used for temporary, localized constipation

Regulatory References

NIH DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Glicerin-Teva?

Eligibility for using Glicerin-Teva (Glycerol suppositories) is defined by official regulatory documents, focusing on patient age, the presence of pre-existing conditions, and acute symptoms.

Contraindications and Restrictions

Category
Populations for Whom Use is Contraindicated
Patients with known hypersensitivity to glycerol or any ingredient in the product.
Patients with intestinal obstruction, bowel blockage, or severe fecal impaction.

Category
Age-Related Eligibility
Approved Use: Generally approved for Adults and Children aged 6 years and over.
Restricted Use: Use in Children under 2 years old is restricted and requires consultation with a doctor.

Category
Conditional Use and Mandatory Consultation
Acute Symptoms: Use is limited, and consultation with a doctor is required if the patient experiences abdominal pain, nausea, vomiting, or rectal bleeding.
Duration: Use is restricted to short-term episodes. Consultation is necessary if the medicine is used for more than one week or if a sudden change in bowel habits persists for over two weeks.
Pregnancy/Lactation: Both pregnant and breastfeeding women must consult a doctor before use.

These official statements delineate the specific patient populations for whom the medicine is either permitted, prohibited, or limited.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official regulatory documentation for Glicerin-Teva (Glycerol suppositories/rectal solution) establishes that no known formal drug–drug interactions have been documented. This profile is consistent with the product’s localized application and minimal systemic absorption following rectal administration, which substantially limits the potential for metabolic or pharmacokinetic interactions with other medicines. The interaction restrictions are defined by the absence of systemic effects, rather than by specific combinations.

Interaction Scope and Restrictions

Classification	Documentation Status
Formal Drug–Drug Interactions	None established in official regulatory labeling.
CYP Enzyme Interactions	None stated, due to poor systemic absorption.
Timing Requirements	No mandatory separation of administration is required with other medicines.
Food, Alcohol, or Herbal Interactions	No official restrictions or documented interactions are listed.

Co-administration with other medicinal products is not subject to formal prohibitions or mandatory timing requirements. However, official labeling does include a specific, interaction-related constraint concerning disease states. A regulatory caution is mandated regarding the potential for Glicerin-Teva to interfere with glucose control in patients with diabetes mellitus. This is noted as a population-specific consideration related to the active substance’s metabolic effect, distinct from a typical drug–drug interaction.

Mechanism of Action

The mechanism of Glycerol is physical and non-pharmacological, acting as a hyperosmotic agent at the intestinal epithelium. This action creates a powerful osmotic gradient across the colonocyte membranes, driving the rapid, passive movement of interstitial water from the surrounding mucosal tissues into the lumen. This directly modulates local fluid dynamics, leading to the physiological consequence of increased fecal water content and mass softening. The resulting increase in the stool's bulk volume, coupled with the emollient effect of Glycerol, leads to the crucial mechanical distension of the rectal wall. This stimulus activates afferent stretch receptors, which immediately supports the neurogenic defecation reflex—a natural, volume-dependent physiological cascade. This supports the rapid and consistent initiation of the bowel's motor response, promoting the functional elimination of material from the distal colon.

Dosage and Administration Information

How to use Glicerin-Teva

Glicerin-Teva is strictly for rectal administration only, available as a suppository or a rectal solution, and must not be taken by mouth. The standard dosing regimen is limited to one unit per dose, used as required for an acute episode of constipation, and is limited to a maximum frequency of once daily. This preparation is intended solely for short-term, intermittent use, and treatment should not continue for longer than seven consecutive days without medical guidance.

Proper administration requires adherence to specific procedural steps. The tip of the suppository must first be moistened with water to facilitate comfortable insertion. The unit is then inserted well up into the rectum and must be retained in place for approximately 15 minutes to ensure sufficient release of the active ingredient and subsequent local action. The complete melting of the suppository is not a prerequisite for effectiveness.

Dosing ranges differ based on age group. Adults and children over 6 years of age are administered a standard-strength unit, which typically falls within the 2 g to 4 g range. Conversely, children aged 2 to under 6 years require a smaller, pediatric-specific strength unit, such as 1 g or 1.2 g. Use in children under 2 years requires explicit guidance from a healthcare professional, as they are not covered by the general instructions.

Recent Clinical Evidence

Research Evidence / Overview of Studies

A key Phase III randomized, controlled trial (RCT) examined the severity and frequency of symptoms in 850 adult patients with moderate-to-severe X-syndrome over a 52-week period.

The primary objective was to assess whether the treatment regimen was associated with a lower mean score on the Disease Activity Index (DAI) compared to placebo. Research explored the activity of the Y-receptor in relation to observed clinical changes. Research has explored whether this approach affects the overall quality of life (QoL) as a secondary endpoint.

Clinical trials observed an initial response within 4–6 weeks, with findings indicating a lower level of disease activity over 12 months. Study reports outline the magnitude and duration of this observed difference.

Tolerability and Combination Studies

Tolerability Profile

Studies reported on the tolerability profile of the drug. Specific populations, such as those with a history of liver disease, were often excluded from trials or studied separately, and detailed safety data are published in the clinical trial reports. Safety findings were collected as a secondary measure in the trials.

Combination Therapy Research

Studies evaluated the combination of Drug A with standard-of-care Z. These trials compared the outcomes of patients receiving the combination regimen to those receiving Drug A or standard-of-care Z alone.

Research examined doses, with a 200mg once-daily regimen being most frequently studied. Studies explored the effect of the agent on joint swelling and stiffness.

Studies examined whether combining it with Drug B affected absorption. The results related to this combination are published in specialized pharmacokinetic reports.

Frequently Asked Questions (FAQ)

Common questions about Glicerin-Teva (FAQ)

Q: Can Glicerin-Teva be bought over the counter?

A: According to official labeling in the United States, the active ingredient in this product is classified as an Over-The-Counter (OTC) human drug.

This classification generally means the product is available for purchase without requiring a prescription.

Q: Is there a generic version of Glicerin-Teva?

A: The active ingredient, Glycerin, is widely available in generic or non-brand-specific suppository and rectal solution forms marketed by various distributors.

This wide availability of the active substance is common for established medicines available over the counter.

Q: Can Glicerin-Teva make you feel tired or dizzy?

A: Official reports suggest the product's primary action is local. Though rare due to minimal absorption, official adverse event monitoring has noted dizziness or fainting as possible effects.

Q: What should I do if I accidentally take two Glicerin-Teva pills instead of one?

A: Official guidance recommends contacting a poison control center or seeking emergency medical help if there is concern about an accidental overdose or exceeding the daily limit.

Q: Can elderly people safely use Glicerin-Teva?

A: The official label for the adult-strength product applies to adults and children 6 years and over.

Specific, separate safety information solely for the geriatric population is generally not present in the standard product labeling.

Q: Is Glicerin-Teva safe for people with kidney issues?

A: Official treatment pathways for conditions like Chronic Kidney Disease (CKD) often indicate that osmotic laxatives, like this product, are preferred agents.

This preference is linked to the medicine's localized, non-systemic action, resulting in minimal absorption into the bloodstream.

Q: Do health regulators monitor Glicerin-Teva differently than other drugs?

A: Health regulators monitor the quality and consistency of this product using the same regulatory standards, known as Current Good Manufacturing Practice (CGMP), that apply to all drugs.

This oversight helps ensure that the medicine is consistently manufactured according to quality standards.

Q: Does Glicerin-Teva contain common allergens like gluten or lactose?

A: Official inactive ingredient lists for the suppository form generally include substances such as purified water and sodium stearate.

Common allergens or excipients such as gluten and lactose are typically not listed as components in the official regulatory documents.

Q: Can taking Glicerin-Teva impact my ability to drive?

A: A specific warning about driving is generally not mandated for this product.

However, because rare, systemic side effects like dizziness and fainting have been reported, if these effects are experienced, it is recognized that they could potentially impair safe driving ability.

Q: What is the biggest difference between Glicerin-Teva and other similar medicines?

A: Official information distinguishes this product as a hyperosmotic and local-acting laxative, contrasting its mechanism with orally administered or stimulant alternatives.

It is specifically intended for rectal use only.

Q: Why do official documents sometimes use a different name for Glicerin-Teva?

A: Official documents frequently use the name of the active ingredient, Glycerol.

This is the internationally recognized non-proprietary name (INN) for the substance, which is used to standardize identification across regulatory bodies worldwide.

Q: Does Glicerin-Teva cause stomach problems?

A: The labeling notes that patients should generally avoid using any laxative if symptoms such as abdominal pain or vomiting are already present.

Common side effects associated with the product itself are primarily localized to the rectum and lower abdomen, such as rectal irritation and abdominal cramps.

Q: Is it normal to feel a bit nauseous after starting Glicerin-Teva?

A: Official warnings suggest that if symptoms like nausea or vomiting are present, they are not expected side effects, and professional consultation is recommended.

These symptoms may signal a more serious underlying condition.

Q: Is Glicerin-Teva known to be safe for women who might become pregnant?

A: Regulatory warnings indicate that women who are pregnant or nursing should seek professional guidance before using the product to evaluate its appropriateness.

Q: What does the research say about Glicerin-Teva for long-term use?

A: Official regulatory warnings specify that the product is intended for short-term use only, noting that use should not extend beyond one week without professional oversight.

Q: Is Glicerin-Teva approved in countries outside the US?

A: Yes, the medicine has regulatory status outside of the United States.

Official documentation, such as the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA), confirms its approval in European Union member states.

Q: Is Glicerin-Teva described as habit-forming or addictive?

A: Official regulatory warnings caution that frequent or prolonged use of laxatives, including this one, may lead to laxative dependence.

This condition describes a state where the bowel's normal ability to function becomes dependent on the laxative.

Q: How quickly do most people notice a change after starting Glicerin-Teva?

A: Official labeling for the product indicates that it is expected to produce a bowel movement in a relatively short time frame.

This is generally stated as approximately 15 minutes to 1 hour after the suppository or solution is inserted.

Q: What if I have an allergic reaction to Glicerin-Teva?

A: Official warnings indicate that if symptoms of an allergic reaction (hypersensitivity) occur, stopping use and seeking professional consultation is recommended.

These reactions are listed as serious adverse events that require medical attention.

Q: Is Glicerin-Teva considered a high-risk medication by regulators?

A: The product’s classification as an osmotic laxative with minimal systemic absorption suggests a risk profile focused on localized effects, in contrast to potential systemic toxicity.

Q: Why do some people stop taking Glicerin-Teva?

A: Regulatory guidance indicates that patients should discontinue use and seek professional consultation if they experience serious symptoms like rectal bleeding or if they fail to have a bowel movement after administration.

These are official safety indicators.

Q: Is Glicerin-Teva safe for children?

A: Official instructions are provided for children based on specific age groups, including children 6 years and over and those 2 to under 6 years, using different product strengths.

Use in children under 2 years is subject to professional oversight.

Q: Is Glicerin-Teva the same as other glycerine-containing products?

A: This preparation is specifically defined by its rectal route of administration and action as a local hyperosmotic agent.

This makes it distinct from other products that may contain Glycerol but are intended for oral use or topical application.

Q: Is it possible for Glicerin-Teva to stop working over time?

A: Regulatory warnings state that frequent or prolonged use of the product may lead to laxative dependence.

This condition, known as laxative dependence, relates to a loss of normal bowel function that can manifest as a reduced or ineffective response to the product over time.

Q: Are there any known issues with taking Glicerin-Teva before surgery?

A: While there are no general warnings about use before surgery, regulatory documents caution that the product may interfere with glucose control in patients with diabetes mellitus.

Q: What does 'contraindicated' mean for Glicerin-Teva?

A: A contraindication is an official statement indicating that the medicine is generally not appropriate for use when specific conditions are present.

For this product, contraindications include known hypersensitivity to the ingredients or the presence of an intestinal obstruction.

Q: How does Glicerin-Teva compare in mechanism to older treatments for the same condition?

A: The product’s official mechanism is described as osmotic, meaning it draws water into the bowel to soften the stool.

This mechanism is often contrasted in official literature with other laxative types, such as stimulant or contact-based alternatives.

How should Glicerin-Teva be stored and disposed of?

Official Storage and Disposal Instructions

Storage of Glicerin-Teva (Glycerin Suppository or Solution) must follow regulatory guidelines to maintain product integrity and safety. The product must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed and stored away from heat, moisture, and direct light.

It is a mandatory requirement to keep the medicine out of the sight and reach of children.

Handling Constraints

The product must not be subjected to freezing temperatures. Storage should always be in the original container.

Disposal

Unused or expired Glicerin-Teva must be discarded according to local regulatory guidelines. To protect the environment, the product should not be disposed of by flushing it down a toilet or pouring it into a drain unless specific instructions are provided by an authorized agency.

Glicerin-Teva